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R. Marocco2, I. Mezzaroma1, G. Passavanti1, P. Vittozzi1,
C. M. Mastroianni1,2 and V. Vullo1
1) Department of Public Health and Infectious Diseases, Sapienza University,
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University, Latina, ItalyAbstractAssociation between hepatitis C virus (HCV) infection and diabetes
has been widely postulated. Little is known about the effect of
direct-acting antiviral agents (DAAs) on glycaemic control. The
aim of our study was to evaluate the glycaemic control
modifications in a case series of HCV-positive diabetic patients
receiving DAAs. We retrospectively evaluated 149 HCV-positive
patients in two different institutions affiliated with Sapienza
University: Policlinico Umberto I of Rome and Ospedale Santa
Maria Goretti of Latina. We were able to identify 29 patients
with type 2 diabetes mellitus (19% of total population) who were
receiving different interferon-free regimens. During-treatment
fasting glucose (FG) values were available for 21 patients, and
analysis revealed a statistically significant reduction (p 0.007);
reduction mean value was −52.86 mg/dL. A glycated
haemoglobin (A1C) value during treatment (at weeks 4, 8 and/or
12) was available for ten patients, and the analysis revealed a
statistically significant reduction (p 0.021) with a reduction mean
value of −1.95%. Six patients (23%) needed to reduce
hypoglycaemic drugs, eight of ten patients showed reduction of
A1C and 14 (67%) of 21 patients showed reduced FG during
treatment. FG and A1C reductions values were independent
from which DAA was present in the regimen, HCV genotype,
body mass index and HIV status. In order to avoid hypoglycaemic
events, diabetic patients receiving DAAs should be closely
monitored for reduction of hypoglycaemic drugs. Furthermore, in
our opinion, diabetes could be considered as an element to
prioritize treatment in those patients with no apparent liver
disease.
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E-mail: paolo.pavone@uniroma1.itIntroductionAssociation between hepatitis C virus (HCV) infection and
diabetes has been widely postulated. Prospective studies have
demonstrated a higher risk of developing type 2 diabetes mel-
litus (T2DM) and insulin resistance in the HCV population,
especially after liver transplantation [1–4]. Little is known
about the effect of direct-acting antiviral agents (DAAs) on
glycaemic control. To our knowledge, only a single case report
has highlighted the possibility of hypoglycaemia during treat-
ment [5]. The aim of our study was to evaluate the glycaemic
control modifications in a case series of HCV-positive diabetic
patients receiving DAAs.MethodsWe retrospectively evaluated 149 HCV-positive patients who
had already completed or at least begun treatment for 1 month
with interferon (IFN)-free regimens at two different institutions
affiliated with Sapienza University: Policlinico Umberto I of
Rome and Ospedale Santa Maria Goretti of Latina. We were
able to identify 29 patients with T2DM (19% of the total pop-
ulation) who were receiving different IFN-free regimens
including sofosbuvir + ribavirin (n = 8), sofosbuvir + simeprevir
(n = 5), ledipasvir/sofosbuvir with or without ribavirin (n = 6),
sofosbuvir + daclatasvir with or without ribavirin (n = 6) and
ombitasvir/paritaprevir/ritonavir with or without dasabuvir and
with or without ribavirin (n = 4). The mean age of the patients
was 59.28 years (range 43–83 years); 24 were men and five
were women, and all were Italian except for one patient from
Egypt. The diabetes diagnosis followed the HCV diagnosis in 19. All rights reserved
FIG. 1. Fasting glucose values at baseline,
at week 4 and at week 8. The paired t-test
showed a statistically significant reduction
between baseline values and during-
treatment values (p = 0.007).
CMI Pavone et al. Decline of fasting glucose 462.e2patients and was a previous diagnosis in seven patients. In the
remaining three patients, the year of diabetes diagnosis was not
reported.
The HCV genotype distribution was as following: 1a geno-
type n = 7, 1b genotype n = 10, 1a/1b genotype n = 1, 2 ge-
notype n = 4, 3 genotype n = 5 and 4 genotype n = 2. Fifteen of
29 patients had received IFN therapy, 20 presented advanced
fibrosis/compensated cirrhosis (defined as liver stiffness
>13 kPa) and four presented advanced liver disease (following
the Child-Pugh B classification criteria). Ten patients were HIV
positive, all with undetectable HIV RNA and CD4+ cells >14%,
with different highly active antiretroviral therapy (HAART)
regimens (including one elite controller not receiving HAART).
All the patients had HCV RNA undetectable at end of treat-
ment or no more than 15 UI/mL at week 4 if still receiving
treatment. All patients except one experienced normalized
liver enzyme values at week 4. Analysis of fasting glucose (FG),
glycated haemoglobin (A1C) and hypoglycaemic drug modifi-
cation were independently prescribed by patients’ reference
diabetologists or family doctors. Nine patients were receiving
metformin, 15 insulin and one repaglinide; four were not
receiving any hypoglycaemic drug. We considered valid as
pretreatment values only those recorded at baseline or within a
maximum of 3 months before the start of DAAs. Using these
criteria, pretreatment FG values were available for 27 patients;
we found the mean value to be 175 mg/dL (minimum 85 mg/dL,
maximum 455 mg/dL). Pretreatment A1C values were available
for 17 patients, with a mean value of 7.1% (minimum 5.1%,
maximum 11.8%).
To compare pretreatment and during-treatment values,
paired t tests were performed by R software.© 2016 European Society of Clinical Microbiology and InResultsDuring-treatment FG values were available for 21 patients (at
weeks 4, 8 and/or 12). Analysis (using week 8 values when
available or, alternatively, week 4) showed a statistically signif-
icant reduction (p 0.007) (Fig. 1), the reduction mean value
was −52.86 mg/dL (with the maximum reduction observed of
357 mg/dL in a patient that switched from 455 to 98 mg/dL at
week 8). An A1C value during treatment (weeks 4, 8 and/or 12)
was available for ten patients. The analysis revealed a statistically
significant reduction (p 0.021), with a reduction mean value
of −1.95% (with the maximum reduction observed of 7.1%
points in a patient who switched from 11.8% to 4.7% at week
8). To better evaluate the improvement of glycaemic control,
we used a composite end point given by reduction of FG (of a
minimum of 20 mg/dL) or A1C (of a minimum of 0.5%) or
reduction of hypoglycaemic drugs dosing during anti-HCV
treatment. Four patients were excluded from the analysis
because data were insufficient (e.g. only one glycaemic value, no
data on hypoglycaemic drugs, no way to make a comparison).
The end point was reached by 21 (84%) of 25 patients. Six
patients (23%) needed to reduce hypoglycaemic drugs (two
patients reduced metformin dosing and four patients reduced
insulin dosing). Eight of 10 patients showed reduction of A1C,
and 14 (67%) of 21 patients showed reduced FG during
treatment.
FG and A1C reductions values were independent of which
DAA was present in the regimen, HCV genotype, body mass
index and HIV status by Kruskal-Wallis test and the Welch
one-way ANOVA procedure (R software). No cases offectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 22, 462.e1–462.e3
462.e3 Clinical Microbiology and Infection, Volume 22 Number 5, May 2016 CMIsymptomatic hypoglycaemia were found. In the four patients
who did not reach the end point, three presented normal
baseline FG (<110 mg/dL) and A1C (<6%) while receiving only
metformin, so no significant reduction of glycaemic values was
expected. The observation that patients with normal baseline
FG and A1C did not experience hypoglycaemia suggests that
the direct hypoglycaemic effect of DAAs or drug–drug in-
teractions with insulin and metformin should be excluded. The
remaining patient who did not experience improvement of
glycaemic control had advanced liver disease (Child-Pugh B)
and was the only patient with persisting elevated liver enzymes
at the end of treatment. Unlike the other patients, he had
worsening of FG values, leading to an increase in his insulin
dose; he also experienced a retinal haemorrhage during
treatment.DiscussionThe mechanisms by which HCV might induce diabetes repre-
sent a critical issue, especially in patients without cirrhosis. In
fact, it can be presumed that in patients with advanced liver
disease the insulin-signalling pathway is also altered by the
presence of cirrhosis itself. In addition, it could be useful to
classify patients with hepatogenous diabetes or hereditary
T2DM to better define the effect of HCV eradication on these
distinct situations [6], but this is not always possible because
there is still no official definition of hepatogenous diabetes in
international guidelines.
This retrospective evaluation of our diabetic HCV-positive
population showed that HCV suppression after DAA treat-
ment was associated with a marked decrease in FG values to
below the normal cutoff after only 4 weeks of treatment. In© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevierorder to avoid hypoglycaemic events, diabetic patients receiving
DAAs should be closely monitored for reduction of hypo-
glycaemic drugs. Furthermore, diabetes could be considered as
an element indicating the need to prioritize treatment in pa-
tients with no apparent liver disease. Prospective studies should
be performed to better define the effect on insulin resistance of
HCV suppression after treatment with the new DAAs.Transparency DeclarationAll authors report no conflicts of interest relevant to this
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